The role of molecular imaging in the differential diagnosis of parkinsonism.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Quarterly Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 22460157
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders

  2011cited by this paper
• PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.

  2011cited by this paper
• Classification of movement disorders

  2011cited by this paper
• Cerebral Glucose Metabolic Features of Parkinson Disease and Incident Dementia: Longitudinal Study

  2011cited by this paper
• Milestones in atypical and secondary Parkinsonisms

  2011cited by this paper
• Diagnostic Accuracy of Combined FP-CIT, IBZM, and MIBG Scintigraphy in the Differential Diagnosis of Degenerative Parkinsonism: A Multidimensional Statistical Approach

  2011cited by this paper
• Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.

  2011cited by this paper
• Sequential imaging analysis using MIBG scintigraphy revealed progressive degeneration of cardiac sympathetic nerve in Parkinson’s disease

  2011cited by this paper
• Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism

  2011cited by this paper
• Differential effects of stress on [11C]raclopride and [11C]MNPA binding to striatal D2/D3 dopamine receptors: A PET study in conscious monkeys

  2011cited by this paper
• Typical cerebral metabolic patterns in neurodegenerative brain diseases

  2010cited by this paper
• Fully automated 3D basal ganglia activity measurement in dopamine transporter scintigraphy (Spectalyzer)

  2010cited by this paper
• Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis.

  2010cited by this paper
• Midbrain SERT in degenerative parkinsonisms: A 123I‐FP‐CIT SPECT study

  2010cited by this paper
• Cardiac autonomic neuropathy in patients with diabetes and no symptoms of coronary artery disease: comparison of 123I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability

  2010cited by this paper
• Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology

  2010cited by this paper
• Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes.

  2010cited by this paper
• Current state of agonist radioligands for imaging of brain dopamine D2/D3 receptors in vivo with positron emission tomography.

  2010cited by this paper
• Validation of cardiac 123I-MIBG scintigraphy in patients with Parkinson’s disease who were diagnosed with dopamine PET

  2009cited by this paper
• Monoamine transporter availability in Parkinson’s disease patients with or without depression

  2009cited by this paper
• Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.

  2009cited by this paper
• [Diagnostic value of cardiac 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy in Lewy body disorders].

  2009cited by this paper
• Serotonin transporter binding with [123I]β-CIT SPECT in major depressive disorder versus controls: effect of season and gender

  2009cited by this paper
• Correlation between body mass index and striatal dopamine transporter availability in healthy volunteers - A SPECT study

  2008cited by this paper
• Abnormal metabolic networks in atypical parkinsonism

  2008cited by this paper
• Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review.

  2008cited by this paper
• 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder.

  2008cited by this paper
• Seasonal variation in human brain serotonin transporter binding.

  2008cited by this paper
• Normal dopamine transporter single photon‐emission CT scan in corticobasal degeneration

  2008cited by this paper
• A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies

  2007cited by this paper
• Changes in network activity with the progression of Parkinson's disease.

  2007cited by this paper
• Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?

  2007cited by this paper
• The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation

  2007cited by this paper
• Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects.

  2007cited by this paper
• Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy

  2007cited by this paper
• Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

  2007cited by this paper
• Abnormal Metabolic Network Activity in Parkinson'S Disease: Test—Retest Reproducibility

  2007cited by this paper
• Assessment of the progression of Parkinson's disease: a metabolic network approach.

  2007cited by this paper
• The Role of 123I-Metaiodobenzylguanidine Myocardial Scintigraphy in the Diagnosis of Lewy Body Disease in Patients with Dementia in a Memory Clinic

  2006cited by this paper
• Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis.

  2006cited by this paper
• New semiquantitative assessment of123I-FP-CIT by an anatomical standardization method

  2006cited by this paper
• Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis.

  2006cited by this paper
• Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration

  2006cited by this paper
• Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies.

  2006cited by this paper
• Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease.

  2006cited by this paper
• The diagnosis of Parkinson's disease.

  2006cited by this paper
• FDG PET in the differential diagnosis of parkinsonian disorders

  2005cited by this paper
• Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients

  2005cited by this paper
• Early-stage [123I]β-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson’s disease

  2005cited by this paper
• Progression of parkinsonism in multiple system atrophy

  2005cited by this paper
• Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies.

  2005cited by this paper
• Validation of [123I]β-CIT SPECT to Assess Serotonin Transporters In Vivo in Humans: a Double-Blind, Placebo-Controlled, Crossover Study with the Selective Serotonin Reuptake Inhibitor Citalopram

  2005cited by this paper
• Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: Implications for clinical studies

  2004cited by this paper
• Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

  2004cited by this paper
• Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy

  2004cited by this paper
• Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy

  2004cited by this paper
• Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET.

  2004cited by this paper
• Dysautonomia in Parkinson's disease: neurocardiological abnormalities.

  2003cited by this paper
• 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy

  2003cited by this paper
• Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration

  2002cited by this paper
• Differentiating multiple system atrophy from Parkinson’s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging

  2002cited by this paper
• Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP

  2002cited by this paper
• The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.

  2002cited by this paper
• Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy

  2002cited by this paper
• Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

  2002cited by this paper
• Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death.

  2001cited by this paper
• Brain dopamine and obesity.

  2001cited by this paper
• [123I]β‐CIT spect in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration

  2000cited by this paper
• Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism.

  2000cited by this paper
• Loss of dopamine uptake sites and dopamine D2 receptors in striatonigral degeneration.

  2000cited by this paper
• Progression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study

  2000cited by this paper
• Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm.

  1999cited by this paper
• PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson’s disease

  1999cited by this paper
• Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration

  1999cited by this paper
• Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

  1999cited by this paper
• Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism

  1999cited by this paper
• Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease

  1998cited by this paper
• Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.

  1997cited by this paper
• Sympathetic cardioneuropathy in dysautonomias.

  1997cited by this paper
• Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.

  1996cited by this paper
• Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age

  1995cited by this paper
• Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data.

  1994cited by this paper
• Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.

  1994cited by this paper
• Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.

  1994cited by this paper
• Anatomic standardization: linear scaling and nonlinear warping of functional brain images.

  1994cited by this paper
• Dopa resistance in multiple‐system atrophy: Loss of postsynaptic D2 receptors

  1993cited by this paper
• Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.

  1993cited by this paper
• Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography

  1992cited by this paper
• Dopamine D1 and D2 receptors in progressive supranuclear palsy: An autoradiographic study

  1992cited by this paper
• Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure.

  1992cited by this paper
• A post-mortem study on striatal dopamine receptors in Parkinson's disease.

  1991cited by this paper
• The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography.

  1991cited by this paper
• A Regional Covariance Approach to the Analysis of Functional Patterns in Positron Emission Tomographic Data

  1991cited by this paper
• The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies

  1990cited by this paper
• Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

  1990cited by this paper
• The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.

  1990cited by this paper
• Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

  1988cited by this paper
• In vivo evaluation of striatal dopamine reuptake sites using 11C‐nomifensine and positron emission tomography

  1987cited by this paper
• Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography.

  1985cited by this paper
• [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.

  1984cited by this paper

• Positron-emission tomography (PET) and single-photon-emission computed tomography (SPECT) Diagnosis of Neurological disorders

  2024influential citation
• Relevance of 18F-DOPA visual and semi-quantitative PET metrics for the diagnostic of Parkinson disease in clinical practice: a machine learning-based inference study

  2023cites this paper
• Update diagnostische Bildgebung des dopaminergen Systems

  2022cites this paper
• Central Nervous System Imaging in Movement Disorders

  2021cites this paper
• Neuroimaging in Parkinson's Disease: necessity or exaggeration?

  2021cites this paper
• PET imaging in dementia

  2021cites this paper
• Role of [18F]-FDG PET in patients with atypical parkinsonism associated with dementia

  2020cites this paper
• Dopamine Transporter Scan (DaTscan)

  2020cites this paper
• Clinical Nuclear Medicine Neuroimaging: An Instructional Casebook

  2020cites this paper
• Scaled Subprofile Modeling and Convolutional Neural Networks for the Identification of Parkinson's Disease in 3D Nuclear Imaging Data

  2019cites this paper
• Brain Imaging in RBD

  2019cites this paper
• Functional Neuroimaging: Single Photon Emission Computed Tomography (SPECT) In Neurological Disorders

  2018cites this paper
• Quantitative Intensity Harmonization of Dopamine Transporter SPECT Images Using Gamma Mixture Models

  2018cites this paper
• The effects of image reconstruction algorithms on topographic characteristics, diagnostic performance and clinical correlation of metabolic brain networks in Parkinson's disease.

  2018cites this paper
• Clinical correlates and advanced processing of the dopamine transporter spect - applications in parkinsonism.

  2017cites this paper
• Positron Emission Tomography and Single-Photon Emission Computed Tomography in Neurology

  2016cites this paper
• Diagnostische Bildgebung des dopaminergen Systems

  2016cites this paper
• Exploring receptor targeting as a tool for preclinical in vivo imaging of the islets of Langerhans

  2016cites this paper
• Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings

  2014cites this paper
• [¹²³I]FP‐CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug‐induced parkinsonisms: a meta‐analysis

  2014cites this paper
• Glucose metabolic patterns in neurodegenerative brain diseases

  2013cites this paper
• Brain imaging with SPECT and PET

  2013cites this paper
• Mapping Changes in Mouse Brain Metabolism with PET/CT

  2013cites this paper
• Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update

  2013cites this paper